araag2/HINT huggingface dataset:
Clinical trial NCT00122863 (phase 3, status: completed)
Conditions: anxiety disorders
ICD codes: F41.1, F41.9, F40.9, F43.22, F41.0, F93.0, F12.980
Drugs: duloxetine hydrochloride, placebo
SMILES: CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients presenting with generalized anxiety disorder (GAD) in the absence of major
             depressive disorder (MDD). Patients must suffer from GAD and not from an adjustment
             disorder or anxiety disorder not otherwise specified (NOS). Symptoms of GAD should not
             be situational in nature.

        Exclusion Criteria:

          -  Any current and primary diagnosis other than GAD. Patients diagnosed with or who have
             a history of MDD within the past 6 months OR patients diagnosed with or who have a
             history of panic disorder, post-traumatic stress disorder (PTSD), or an eating
             disorder within the past year OR patients who have been diagnosed with obsessive-
             compulsive disorder (OCD), bipolar affective disorder, psychosis, factitious disorder
             or somatoform disorders during their lifetime.

          -  History of alcohol or any psychoactive substance abuse of dependence (as defined in
             the DSM-IV-TR) within the past 6 months

          -  Serious medical illness, including cardiovascular, hepatic, renal, respiratory,
             hematologic, endocrinologic, or neurologic disease, or clinically significant
             laboratory abnormality that is not stabilized or is anticipated to require
             hospitalization within 6 months, in the opinion of the investigator. Clinically
             significant laboratory abnormalities are those, that, in the judgement of the
             investigator, indicate a serious medical problem.

          -  Acute liver injury (such as hepatitis) or severe cirrhosis (Child- Pugh Class C)
Clinical trial NCT00566631 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Meets the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
             criteria for schizophrenia

          -  Must be experiencing an acute schizophrenic episode with a Positive and Negative
             Syndrome Scale (PANSS) total score of greater than or equal to 70 at Baseline

          -  Must be admitted to hospital for treatment of the acute schizophrenic episode and must
             agree for voluntary hospitalization for at least the first 7 days of the study

          -  Female participants must be postmenopausal (for at least 1 year), surgically sterile,
             abstinent, or, if sexually active, be practicing and effective method of birth control
             (example, prescription oral contraceptives, contraceptive injections, intrauterine
             device, double-barrier method, contraceptive patch, male partner sterilization) before
             entry and throughout the study and female participants of child-bearing potential must
             have a negative urine pregnancy test at Screening

          -  Participants or their legally acceptable representatives must have signed an informed
             consent document indicating that they understand the purpose of and procedures
             required for the study and are willing to participate in the study

        Exclusion Criteria:

          -  Pregnant or breast-feeding female participants

          -  First antipsychotic treatment ever

          -  Have received an experimental drug or used an experimental medical device within 30
             days before the planned start of treatment and on clozapine or a long-acting
             injectable antipsychotic during the last 3 months

          -  Known hypersensitivity to paliperidone extended-release (ER) or risperidone

          -  Relevant history of any significant or unstable cardiovascular, respiratory,
             neurologic (including seizures or significant cerebrovascular), renal, hepatic,
             endocrine, or immunologic diseases, history or current symptoms of tardive dyskinesia
             or neuroleptic malignant syndrome including recent or present clinically relevant
             laboratory abnormalities (as deemed by the Investigator) and participants with current
             or known history (over the past 6 months) of substance dependence according to DSM-IV
             Criteria
Clinical trial NCT01529632 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: qva149, nva237, qab149, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged ≥ 40 yrs

          -  Smoking history of at least 10 pack years

          -  Diagnosis of COPD (moderate to severe as classified by the Global Initiative for
             Chronic Obstructive Lung Disease (GOLD) Guidelines, 2010)

          -  Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value and
             post-bronchodilator FEV1/FVC (forced vital capacity) < 70%

        Exclusion Criteria:

          -  Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular co-morbid conditions

          -  Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency

          -  Patients in the active phase of a supervised pulmonary rehabilitation program

          -  Patients contraindicated for inhaled anticholinergic agents and β2 agonists

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01606228 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed with schizophrenia

          -  Patient with Positive and Negative Syndrome Scale (PANSS) score of 80 to 120 at
             screening

          -  Patients who have not taken any antipsychotics in the past, and those were newly
             diagnosed with schizophrenia who have not taken any antipsychotics for at least one
             month prior to screening

          -  Patient healthy on the basis of a physical examination, laboratory examination, and
             vital signs

          -  Women must have a negative pregnancy test, and agree to practice an effective method
             of birth control before entry and throughout the study

        Exclusion Criteria:

          -  Serious unstable medical condition, including known clinically relevant laboratory
             abnormalities

          -  Judged to be at high risk for adverse events, violence or self-harm

          -  Inability to swallow the study medication whole with the aid of water (patients may
             not chew, divide, dissolve, or crush the study medication)

          -  Biochemistry results that are out of the laboratory's normal reference range and are
             deemed to be clinically significant by the investigator

          -  Patients with a current use or known history (over the past 6 months) of substance
             dependence

          -  Positive urine drug examination
Clinical trial NCT00243178 (phase 3, status: terminated)
Conditions: atrial fibrillation, vascular risk
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20, G21.4, G95.19, I67.3, H34.9, I73.9, Q79.63, Z98.62
Drugs: clopidogrel (sr25990c)
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Evidence of atrial fibrillation either on one current Electrocardiogram (ECG) or on
             two ECG recorded at two weeks a part during 6 months prior to study enrollment.

          -  Evidence of high risk of vascular events: at least one of the following risk criteria
             must be present:

               -  are 75 years or greater;

               -  on treatment for systemic hypertension;

               -  prior stroke, TIA, or non-CNS systemic embolus;

               -  left ventricular dysfunction with left ventricular ejection fraction (EF)
                  estimated by echocardiogram or angiogram (radionuclide or contrast) to be < 45%;

               -  peripheral vascular disease (previous peripheral artery revascularization, limb
                  and foot amputation, or the combination of current intermittent claudication and
                  ankle arm systolic blood pressure ratio < 0.9);

               -  age 55 to 74 years; AND

               -  either diabetes mellitus requiring drug therapy, or documented previous
                  myocardial infarction, or documented coronary artery disease.

        Exclusion Criteria:

          -  Patients will be excluded from ACTIVE if any of the following are present :

               -  requirement for clopidogrel (such as recent coronary stent procedure);

               -  requirement for oral anticoagulant (such as prosthetic mechanical heart valve);

               -  prior intolerance to ASA or clopidogrel;

               -  documented peptic ulcer disease within the previous 6 months;

               -  prior intracerebral hemorrhage;

               -  significant thrombocytopenia; (platelet count < 50 x 10(9)/L);

               -  psychosocial reason making study participation impractical;

               -  geographic reason making study participation impractical;

               -  ongoing alcohol abuse;

               -  mitral stenosis;

               -  pregnant or nursing woman or woman of child bearing potential and not on
                  effective birth control for at least one month prior to start of study or not
                  willing to continue on birth control for duration of study;

               -  severe comorbid condition such that the patient is not expected to survive 6
                  months;

               -  patient currently receiving an investigational pharmacologic agent; OR

               -  requirement for chronic (> 3 months) non-COX-2 inhibitor NSAID therapy.
Clinical trial NCT01098539 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Renally impaired with a historical diagnosis of type 2 diabetes mellitus and is
             experiencing inadequate glycemic control on their current regime of diet and exercise
             or their antidiabetic therapy of metformin, TZD, SU, or any combination of these oral
             antidiabetic medications

          -  BMI >/=20 kg/m2 and </=45 kg/m2

          -  Fasting C-peptide >/=0.8 ng/mL (>/=0.26 nmol/L)

          -  HbA1c between 7.0% and 10.0%, inclusive.

        Exclusion Criteria:

          -  History of cancer

          -  History of treated diabetic gastroparesis

          -  Current biliary disease or history of pancreatitis

          -  History of significant gastrointestinal surgery

          -  Recent clinically significant cardiovascular and/or cerebrovascular disease

          -  History of human immunodeficiency virus infection

          -  Abnormal liver function or acute symptomatic infection with hepatitis B or hepatitis C

          -  Female subject is pregnant (confirmed by laboratory testing), lactating, or <6 weeks
             postpartum

          -  Known allergy to any GLP 1 analogue, sitagliptin, other study medications' excipients,
             excipients of albiglutide, or Baker's yeast

          -  Receipt of any investigational drug or sitagliptin within the 30 days or 5 half lives,
             whichever is longer, before Screening or a history of receipt of an investigational
             antidiabetic drug within the 3 months before randomization or receipt of albiglutide
             in previous studies
Clinical trial NCT01613326 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: nva237, tiotropium, placebo to tiotropium, placebo to nva237, salbutamol/albuterol
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with moderate to severe stable COPD (Stage II or Stage III) according to the
             current GOLD Guidelines (GOLD 2010).

          -  Patients with a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) ≥ 30%
             and < 80% of the predicted normal, and a post-bronchodilator FEV1/ Forced Vital
             Capacity (FVC) < 0.70 at screening

          -  Current or ex-smokers who have a smoking history of at least 10 pack years (e.g. 10
             pack years = 1 pack/day x 10 yrs, or ½ pack/day x 20 yrs).

          -  Symptomatic patients, according to daily electronic diary data between Visit 2 (Day
             -14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7
             days prior to Visit 3.

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  Patients who, in the judgment of the investigator, or the responsible Novartis
             personnel, have a clinically relevant laboratory abnormality or a clinically
             significant condition before Visit 1.

          -  Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or
             bladder-neck obstruction or moderate to severe renal impairment or urinary retention.
             (BPH patients who are stable on treatment can be considered).

          -  Patients receiving medications in the classes listed in the protocol as prohibited.

        Other protocol-defined inclusion/exclusion criteria apply and can be found in the study
        protocol
Clinical trial NCT00531622 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: saredutant (sr48968), escitalopram, placebo
SMILES: CN(C[C@@H](CCN1CCC(CC1)(NC(C)=O)C1=CC=CC=C1)C1=CC=C(Cl)C(Cl)=C1)C(=O)C1=CC=CC=C1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients with recurrent Major Depressive Disorder

        Exclusion Criteria:

          -  Symptoms of current depressive episode for less than 30 days or more than 2 years

          -  Mild depression, as measured by standard clinical research scales

          -  Significant suicide risk

          -  Lack of sexual activity (including masturbation)

          -  Other psychiatric conditions that would obscure the results of the study

          -  History of failure to respond to antidepressant treatment

          -  Pregnancy or breast-feeding

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00351169 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: quetiapine sr, escitalopram
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 to 65 years

          -  A documented diagnosis of major depressive disorder

        Exclusion Criteria:

          -  Patients with a DSM IV Axis I disorder other than MDD within 6 months of enrolment

          -  Patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the
             patient's current psychiatric status

          -  Patients whose current episode of depression exceeds 12 months or is less than 4 weeks
             prior to enrolment
Clinical trial NCT00003958 (phase 3, status: completed)
Conditions: adult malignant mesenchymoma, adult rhabdomyosarcoma, alveolar childhood rhabdomyosarcoma, childhood malignant mesenchymoma, embryonal childhood rhabdomyosarcoma, embryonal-botryoid childhood rhabdomyosarcoma, nonmetastatic childhood soft tissue sarcoma, previously untreated childhood rhabdomyosarcoma, stage i adult soft tissue sarcoma, stage ii adult soft tissue sarcoma, stage iii adult soft tissue sarcoma
ICD codes: R18.0, C17.3, G21.0, J91.0, C05.2, C10.0, C16.0, F80.81, F84.3, F93.8, F93.9, R62.0, E71.520, F64.2, F80.81, F84.3, F93.8, F93.9, R62.0, E71.520, F64.2
Drugs: vincristine sulfate, cyclophosphamide, topotecan hydrochloride
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven disease of any of the following types:

               -  Non metastatic alveolar rhabdomyosarcoma

                    -  Stage I, II, or III; Clinical Group I, II, or III

               -  Stage II or III, Clinical Group III embryonal rhabdomyosarcoma

                    -  Botryoid

                    -  Spindle cell

               -  Under 10 years, stage IV, Clinical Group IV embryonal rhabdomyosarcoma

                    -  Botryoid

                    -  Spindle cell

               -  Undifferentiated sarcoma

                    -  Stage I, II, or III; Clinical Group I, II, or III

               -  Ectomesenchymoma

                    -  Stage I, II, or III; Clinical Group I, II, or III, with alveolar features

                    -  Under 10 years, Stage IV, Clinical Group IV, with embryonal features

          -  No more than 6 weeks since initial surgical procedure (e.g., biopsy) giving the
             definitive diagnosis

          -  No parameningeal rhabdomyosarcoma with positive CSF cytology or multiple intracranial
             metastases

          -  Bilirubin no greater than 1.5 mg/dL

          -  Creatinine normal* for age

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No prior chemotherapy

          -  Prior steroids allowed

          -  No prior radiotherapy

          -  See Disease Characteristics
Clinical trial NCT00289848 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate, comparator: placebo
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Patients have Type 2 Diabetes Mellitus and have laboratory results that are within the
             values established by the study such as an Hemoglobin A1c (HbA1c) >=7.5% and <=11% and
             a Fasting Plasma Glucose (FPG) >=130 mg/dL and <=280 mg/dL

        Exclusion Criteria :

          -  Patients have Type 1 Diabetes Mellitus or required insulin therapy within the past 12
             months
Clinical trial NCT00519142 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo for mitiglinide, mitiglinide, mitiglinide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O, [H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  type 2 diabetes diagnosed for at least 6 months

          -  stable metformin usage for at least 4 months

          -  HbA1c 7.5% - 10.5% inclusive

          -  no severe diabetic complications

        Exclusion Criteria:

          -  chronic insulin use

          -  use of oral diabetic agent within 12 weeks

          -  acute or chronic conditions, excluding diabetes, that could compromise end point
             evaluation
Clinical trial NCT00415194 (phase 3, status: completed)
Conditions: head and neck neoplasms
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: pemetrexed, cisplatin, placebo
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  You must have head and neck cancer that has returned and cannot be treated with
             surgery or other types of treatment. OR You must have head and neck cancer that was
             just found and has spread to other parts of your body.

          -  You must have a performance status of 0,1 or 2. This means that you must at least be
             able to get around, be able to take care of yourself and must be up and about most of
             the day.

          -  Your test results must show that your liver, kidneys and blood cells are working
             normally.

          -  You must understand and sign the form that gives your agreement to willingly be part
             of the study.

          -  You must be at least 18 years of age.

        Exclusion Criteria:

          -  You cannot have previously been given other treatment for cancer that has spread to
             other parts of your body.

          -  You cannot have a serious sickness that might keep you from finishing the study (for
             example a bad infection).

          -  You cannot have any extra fluid in your chest or bowel area unless your doctor tells
             you it can be drained before you join the study.

          -  You cannot have any cancer called nasopharyngeal cancer, paranasal sinus cancer, lip
             cancer, or salivary gland cancer.

          -  If you are taking high dose aspirin or other medicines called non-steroidal
             anti-inflammatory drugs and cannot stop taking them for at least 5 days, you cannot be
             in the study. Your doctor or a member of the study team can explain which drugs are
             non-steroidal anti-inflammatory drugs.